For one thing, the medication comes with potential side effects, including nausea, vomiting, diarrhea, constipation, and abdominal pain
The FDA approved Wegovy for cardiovascular risk reduction in adults with established cardiovascular disease who are also overweight in March 2024, which opened the door for Medicare coverage in that specific population
Powered byLiposomal Glutathione 90%delivering600 mg glutathione, this high-potency formula uses phospholipid encapsulation for 4x higher bioavailability
Reduced levels of NAA along with glutamate suggest decrease in viability of glutamatergic neurons in depression
If you find yourself not losing weight despite using GLP-1 medication, discussing your concerns with your healthcare provider is vital